Table 1. Clinical cohort characteristics.
| Characteristic | HIV- (n = 98) | HIV+CD4 500+ (n = 34) | HIV+CD4 200–499 (n = 43) | HIV+CD4 <200 (n = 21) |
|---|---|---|---|---|
| Median age (range) | 42 (25–76) | 43 (29–56) | 40 (29–64) | 44 (27–66) |
| HSV1-coinfected | 63 (64%) | 19 (56%) | 27 (63%) | 17 (81%) |
| Time since HSV2 acquisition | ||||
| 1–9 years | 34 (35%) | 11 (32%) | 14 (33%) | 9 (43%) |
| 10+ years | 26 (27%) | 6 (18%) | 14 (33%) | 6 (29%) |
| Unknown (no history at enrollment) | 30 (31%) | 14 (41%) | 10 (23%) | 6 (29%) |
| Unknown (history of lesions at enrollment) | 8 (8%) | 3 (9%) | 5 (12%) | 0 (0%) |
| Using ARVs | ||||
| None | — | 14 (41%) | 18 (42%) | 3 (14%) |
| Non-HAART ARVs | — | 1 (3%) | 5 (12%) | 7 (33%) |
| HAART | — | 18 (53%) | 20 (47%) | 10 (48%) |
| Unknown | — | 1 (3%) | 0 (0%) | 1 (5%) |
| Median HIV RNA (IQR) | — | 420 (15-10K) | 3K (60-25K) | 29K (5K-98K) |
| HIV RNA category | ||||
| <10K | — | 26 (76%) | 26 (60%) | 10 (48%) |
| 10K-49K | — | 5 (15%) | 10 (23%) | 4 (19%) |
| 50K+ | — | 3 (9%) | 7 (16%) | 7 (33%) |
| Median CD4 count /μL (IQR) | — | 610 (535–735) | 320 (240–400) | 130 (85–160) |
| Total episodes (a maximum of 10 episodes were counted per person) | 173 | 55 | 95 | 58 |